Taro Pharm Inds (TARO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 06-2021 | 03-2021 | 12-2020 | 09-2020 | 06-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 614,888 | 605,177 | 552,918 | 498,796 | 532,044 |
| Marketable Securities | 410,590 | 418,480 | 521,041 | 543,204 | 590,286 |
| Receivables | 272,429 | 266,886 | 278,788 | 276,617 | 234,383 |
| Inventories | 182,860 | 180,292 | 169,527 | 167,213 | 166,223 |
| TOTAL | $1,480,767 | $1,470,835 | $1,522,274 | $1,485,830 | $1,522,936 |
| Non-Current Assets | |||||
| PPE Net | 202,031 | 205,508 | 206,296 | 207,923 | 209,228 |
| Investments And Advances | 568,878 | 557,209 | 476,248 | 476,800 | 510,397 |
| Intangibles | 0 | 7,191 | 0 | 0 | 0 |
| Other Non-Current Assets | 161,629 | 166,130 | 167,006 | 175,555 | 137,132 |
| TOTAL | $932,538 | $936,038 | $849,550 | $860,278 | $856,757 |
| Total Assets | $2,413,305 | $2,406,873 | $2,371,824 | $2,346,108 | $2,379,693 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 62,066 | 61,166 | 45,409 | 39,967 | 36,302 |
| Other current liabilities | 667,084 | 615,135 | 538,668 | 547,349 | 560,185 |
| TOTAL | $729,150 | $676,301 | $584,077 | $587,316 | $596,487 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 32,304 | -117 | 70 | 15,038 |
| TOTAL | $26,099 | $35,115 | $37,174 | $40,047 | $109,068 |
| Total Liabilities | $755,249 | $711,416 | $621,251 | $627,363 | $705,555 |
| Shareholders' Equity | |||||
| Common Shares | N/A | 679 | N/A | N/A | N/A |
| Retained earnings | N/A | 2,338,617 | N/A | N/A | N/A |
| Other shareholders' equity | 1,658,056 | -160,284 | 1,750,573 | 1,718,745 | 1,674,138 |
| TOTAL | $1,658,056 | $1,695,457 | $1,750,573 | $1,718,745 | $1,674,138 |
| Total Liabilities And Equity | $2,413,305 | $2,406,873 | $2,371,824 | $2,346,108 | $2,379,693 |